Trained innate immunity and atherosclerosis
S Bekkering, LAB Joosten… - Current opinion in …, 2013 - journals.lww.com
Current opinion in lipidology, 2013•journals.lww.com
We describe the hypothesis that this functional reprogramming of monocytes, either by
microbial products or by metabolic products, contributes to atherogenesis and propose
epigenetic reprogramming of monocytes as a novel pharmacological target for preventing or
treating atherosclerosis in the future.
microbial products or by metabolic products, contributes to atherogenesis and propose
epigenetic reprogramming of monocytes as a novel pharmacological target for preventing or
treating atherosclerosis in the future.
Summary
We describe the hypothesis that this functional reprogramming of monocytes, either by microbial products or by metabolic products, contributes to atherogenesis and propose epigenetic reprogramming of monocytes as a novel pharmacological target for preventing or treating atherosclerosis in the future.
Lippincott Williams & Wilkins